neurology

News

Novo leads $100m financing for Alzheimer's player Asceneuron

Novo Nordisk's parent company, Novo Holdings, has led a $100 million third-round financing for Swiss biotech Asceneuron, which is developing a non-amyloid therapy for Alzheimer's disease.

News

uniQure rockets on Huntington’s gene therapy result

Shares in gene therapy developer uniQure have risen more than 75% after the company reported that Huntington’s disease candidate AMT-130 slowed down the progression of the disorder over two

News

NeuroSense says ALS drug extends survival

NeuroSense Therapeutics is currently facing de-listing from the Nasdaq, so encouraging data from a phase 2b trial of its PrimeC drug candidate for amyotrophic lateral sclerosis (ALS) comes

News

Blood test could spot Parkinson’s years earlier

An artificial intelligence-powered blood test that may be able to predict Parkinson’s disease several years before symptoms start to develop could allow earlier treatment and help guide the

News

ALZpath licenses Alzheimer’s diagnosis tech to Roche

Diagnostics giant Roche is putting its weight behind a biomarker for Alzheimer’s disease developed by ALZpath.

News

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busti

Novo leads $100m financing for Alzheimer's player Asceneuron

uniQure rockets on Huntington’s gene therapy result

NeuroSense says ALS drug extends survival

Blood test could spot Parkinson’s years earlier

ALZpath licenses Alzheimer’s diagnosis tech to Roche

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

neurology

Editor's Picks